Edition:
United States

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

47.54USD
2:56pm EDT
Change (% chg)

$1.00 (+2.15%)
Prev Close
$46.54
Open
$46.67
Day's High
$48.26
Day's Low
$46.67
Volume
45,690
Avg. Vol
108,186
52-wk High
$52.76
52-wk Low
$12.04

Chart for

About

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38... (more)

Overall

Beta: --
Market Cap(Mil.): $1,554.77
Shares Outstanding(Mil.): 32.70
Dividend: --
Yield (%): --

Financials

  GTHX.OQ Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -2.48 -- --
ROI: -63.72 -3.67 13.17
ROE: -134.40 -5.61 15.10

BRIEF-G1 Therapeutics Reports Qtrly Loss Per Share Of $0.70

* G1 THERAPEUTICS PROVIDES FIRST QUARTER 2018 CORPORATE AND FINANCIAL UPDATE

May 03 2018

BRIEF-G1 Therapeutics Files For Offering Of 3 Mln Shares

* FILES FOR OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK Source text: (http://bit.ly/2D2beLO) Further company coverage:

Mar 05 2018

BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer

* G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER

Mar 05 2018

BRIEF-G1 Therapeutics Qtrly Net Loss Per Share $0.60

* G1 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

Feb 21 2018

Earnings vs. Estimates